MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

BACKGROUND: CB(2) (cannabinoid receptor 2) agonists have been shown to exert anti-tumor activities in different tumor types. However, there is no study exploring the role of MDA19 (a novel CB(2) agonist) in tumors. In this study we aimed to investigate the effects of MDA19 treatment on HCC cell line...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Mei, Chen, Dongfeng, Zhan, Peng, Jiang, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500002/
https://www.ncbi.nlm.nih.gov/pubmed/31053086
http://dx.doi.org/10.1186/s13062-019-0241-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500002/
https://www.ncbi.nlm.nih.gov/pubmed/31053086
http://dx.doi.org/10.1186/s13062-019-0241-1

Ejemplares similares